NCT03477539View on ClinicalTrials.gov

Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

April 9, 2018

Primary Completion Date

December 18, 2026

Study Completion Date

December 18, 2026

Conditions

Plasma Cell Myeloma

Interventions

PROCEDURE

Autologous Hematopoietic Stem Cell Transplantation

Undergo ASCT

BIOLOGICAL

Daratumumab

Given IV

DRUG

Lenalidomide

Given PO

Trial Locations (1)

32224-9980

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Mayo Clinic

OTHER